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ABSTRACT
Clonidine and Naltrexone:
Rapid Treatment of Opioid Withdrawal in the Outpatient Setting

Eugenia Marie Vining
1987

Clonidine hydrochloride (an alpha-2 adrenergic agonist) and
naltrexone hydrochloride (an opioid antagonist), given in
combination, provide a safe and effective treatment of abrupt
opioid withdrawal over 4 or 5 days in an outpatient/day
setting.

Following a naloxone challenge test to verify and

quantify opioid dependence, fourteen of 17 (82%) heroin users
successfully withdrew from opioids and attained maintenance
levels of naltrexone.

Eight of 9 (89%) successfully completed

the 5 day study in which naltrexone therapy was begun on day
2.

Six of 8 (75%) successfully completed the 4 day study in

which naltrexone therapy was begun on day 1.

Three to 5 days

of clonidine hydrochloride treatment with a peak mean dose of
0.6 mg/day on day 2 for the patients in the 5 day study, and
0.5 mg on days 1 and 2 for patients in the 4 day study,
attenuated the withdrawal inducing effects of naltrexone.

Both

groups received naltrexone in single morning doses which were
rapidly increased from 12.5 mg on the first day of naltrexone
therapy to 50 mg on the third day.

Significant correlations

were observed between naloxone challenge test score and
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observer-rated symptomatology during treatment.

Clonidine

significantly decreased blood pressure in both groups without
producing clinical problems.

This study has improved the

availability of the clonidine-naltrexone combination by
developing a single dose per day naltrexone regimen with
naltrexone doses generally available to any opioid treatment
facility.

V

1
INTRODUCTION

The last of the codeine was running out. My nose and eyes
began to run, sweat soaked through my clothes. Hot and cold
flashes hit me as though a furnace door was swinging open and
shut. My legs ached and twiched so that any position was
intolerable, and I moved from one side to the other, sloshing
about in my sweaty clothes.
William S. Burroughs, Junkv 1953

Opioid withdrawal, so vividly described by William S. Burroughs
in his powerful account of heroin addiction, is a syndrome of
autonomic disturbance and psychic distress which drives the addict
to continued opioid use.

This abstinence syndrome as well as

tolerance to the effects of increasing amounts of opioids characterize
opioid dependence (APA, 1980).

Successful treatment of opioid

dependence involves treatment of the withdrawal syndrome and
assistance afterward so that the former addict can remain drug-free.
At the turn of the century, treatment of narcotic addiction was
often considered synonymous with successful withdrawal.

New

treatments were advanced periodically and then discarded as
ineffective and often harmful.

Sodium thiocyanate, lipids, sodium

bromide, insulin and other hormones were just some of the agents
used to "treat" opioid withdrawal (Kleber, 1982).

One of the most

popular methods of detoxification at this time employed belladonna
agents (Kolb and Himmelsbach, 1938).

Scopolomine was

administered every 30 to 60 minutes over a one to two day period.
During this detoxification patients would hallucinate and become
wildly delirious, symptomatic of belladonna toxicity.

Fortunately,

such treatments were denounced as more distressing and harmful to
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addicts than withdrawal itself; however, this was not until a number
of deaths had already resulted from them.
In their review article criticizing many of these forms of
treatment, Kolb and Himmelsbach proposed a "rapid withdrawal"
method of detoxification in which doses of morphine and codeine
would be gradually tapered over a seven day period (Kolb and
Himmelsbach, 1938).

This method of detoxification would dominate

treatment modalities until the discovery of methadone during the
Second World War (Isbell et al, 1947).

In addition, citing faulty

observation of the course of withdrawal as the cause for failure of
previous

"treatments,"

these investigators outlined a quantitative

method for measuring abstinence syndrome intensity.

This method

enabled objective evaluation of future treatment modalities and
became the model for present day abstinence rating scales.
Methadone was synthesized by the Germans during World War II,
and soon underwent intensive clinical investigation in the United
States (Isbell et al, 1947; Isbell et al, 1948).

These studies revealed

that methadone was an addictive substance that produced an
abstinence syndrome with milder, more prolonged symptoms than
morphine or heroin (Isbell et al, 1948).

Investigators also found that

methadone could prevent the abstinence syndrome in morphine
dependent patients (Isbell et al, 1948).
the advantages of this cross tolerance.

Researchers quickly realized
Placing morphine or heroin

dependent patients on methadone would substitute the more intense
abstinence syndrome produced by these short-acting opiates with
the much milder withdrawal from methadone.

Soon methadone was

being used as an agent for detoxifying opioid addicts (Isbell and
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Vogel, 1949).

In these initial studies, methadone would be

substituted for the opioid of abuse, and gradually tapered over a 7 to
10 day period (Isbell and Vogel, 1949).
Since the work of Isbell and Vogel in 1949, investigators have
conducted many studies examining the efficacy of both inpatient and
outpatient methadone detoxification.

In their study comparing the

cost and effectiveness of hospital versus outpatient detoxification,
Wilson and his collegues reviewed previous detoxification studies
using methadone (Wilson et al, 1975).

In these studies, methadone

was administered over time periods ranging from 2 weeks to 11
months on both an inpatient and outpatient basis.

Only 3% to 25% of

patients were able to successfully complete detoxification.

Follow-up

of those patients further demonstrated that only 7% to 19% of
patients who had been successfully withdrawn remained drug-free 6
months after treatment (Wilson et al, 1975).
Wilson's own study used a 10 day methadone regimen to detoxify
40 heroin addicts, 10 in the hospital, and 30 in an outpatient setting
(Wilson et al, 1975).

One inpatient (10%) and 6 outpatients (20%)

completed the detoxification.

No inpatients (0%) and only 2

outpatients (7%) remained drug-free 2 months after the
detoxification was complete.

The authors concluded that there was

little benefit from either treatment approach, but that outpatient
therapy was no less successful than inpatient.

Outpatient trials

employing 7 day and 90 day protocols demonstrated successful
detoxification rates of 32% and 13%, respectively (Silsby and
Tennant, 1974; Wilson et al, 1974).

Six months following the
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detoxification, 9.5% of those from the 7 day study and none of those
from the 90 day study were drug-free.
Senay, Dorus, and Showalter examined the 21 day methadone
detoxification recommended by the Food and Drug Administration
and compared it to an 84 day methadone detoxification under
double-blind conditions (Senay et al, 1981).

They found that 4 of 32

(13%) patients completed the 21 day detoxification; however, none of
these patients completed the full 90 day protocol.

Five of 36 (14%)

patients completed the 84 day detoxification and went on to
complete the full 90 day protocol.

All of these patients had remained

drug-free in the follow-up period of 12 months or less (mean = 4.1
months).

They concluded that although the percentage of patients

remaining drug-free was not large in either group, the more gradual
84 day schedule increased the probability that patients would
remain in treatment, without increasing their chances of becoming
severely dependent on methadone (Senay et al, 1981).
The concern that short term management of opioid withdrawal
with methadone might lead to long term dependence on this agent
was not unfounded.

Methadone maintenance programs were initially

established to ensure a "stable addiction" for patients, obviating the
need for heroin as well as the criminal activity often necessary to
support heroin use (Dole and Nyswander, 1967; Bowden and Maddux,
1972).

Orally administered methadone at a certain dose level does

not appear to have a euphoric effect, but induces a marked, slowly
developing tolerance to all opiate-like drugs, including methadone
itself (Jaffe and Martin, 1985).

As a result, the patient cannot feel

the euphoric effect of ordinary doses of other narcotics such as
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heroin or morphine.

Methadone maintenance stabilizes the patient's

a physiologic dependence, affording him the opportunity to modify
his life in other areas: to achieve some stability in his family and
other interpersonal relationships and to move away from
involvement with heroin users and the subculture such use
engenders.

Although methadone maintenance has achieved a certain

amount of success in moving the addict toward socially productive
behavior,
1981).

it has problems associated with its use (Szara and Bunney,

Because it is an opioid agonist with addictive potential,

diversion to illegal channels is one of these problems.

In addition,

once on methadone maintenance, it has been difficult for the patient
to achieve abstinence from methadone, an important goal of
treatment.
Kleber's review of studies examining detoxification from
methadone maintenance demonstrates varying success rates (Kleber,
1977).

Successful detoxification of those felt "appropriate for

detoxification," that is, those in good standing who were not being
discharged from the program, ranged from 8% to 53% (Kleber, 1977).
Relapse even after successful detoxification was considerable with
only 20% to 33% of patients drug-free in a follow-up period of less
than two years.

One study has demonstrated quite successful

withdrawal and follow-up statistics.

Riordan and colleagues

reported on 59 patients on methadone maintenance who were in
good standing and underwent voluntary withdrawal (Riordan et al,
1976).

Of this group, 49 (84%) successfully completed detoxification.

Of the 38 individuals followed-up at time periods ranging from 6 to
44 months after detoxification, 26 (68%) had remained drug-free.
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Despite these more optimistic results, investigators have
continued to search for methods of detoxification that were more
rapid and effective than methadone, without using opioid agonists or
other addictive substances.

Their efforts were facilitated by

discoveries leading to a better understanding of the
neuropharmacology of opioid dependence and withdrawal.

Chronic

administration of opioids produces profound effects on endogenous
opioid function and noradrenergic activity in the central nervous
system (Korf et al, 1974; Hollt et al, 1978; Herz et al, 1978; Przelocki
et al, 1979).

Although long term opioid administration does not

appear to alter enkephalin levels, it does decrease endorphin
synthesis as well as functional sensitivity to opioid agonists (Herz et
al, 1978; Przelocki et al, 1979).

In addition, studies of the brain's

major noradrenergic nucleus, the locus coeruleus (LC), demonstrated
that the prototype opiate morphine causes a marked reduction in LC
neuronal firing rate (Korf et al, 1974).

This decrease in LC activity

and norepinephrine release is followed by a reciprocal increase in
alpha-2 and beta adrenergic receptors in areas receiving LC
projections (Llorens et al, 1978; Hamburg and Tallman, 1981).

These

data suggest an important role for the LC in opioid dependence
withdrawal:

some of the effects of opioids might be mediated

through a decrease in LC activity and noradrenergic release.

The

discovery of specific opioid receptors in the brain (Hughes, 1975),
with a high concentration located in the LC (Pert et al, 1975) was
further evidence supporting such a mechanism.
Studies in rodents and primates provided additional data
implicating the neurotransmitter norepinephrine in opioid
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dependence and withdrawal (Redmond,

1977; Cedarbaum and

Aghajanian, 1977; Svensson et al, 1975; Meyer and Sparber, 1976).
Gunne had previously shown that total brain norepinephrine
decreased during opioid withdrawal suggesting that withdrawal was
associated with increased norepinephrine release (Gunne,

1959).

Cedarbaum and his colleagues found that an intravenous dose of the
alpha-2 adrenergic agonist clonidine inhibited the spontaneous firing
of brain norepinephrine-containing neurons in the LC by acting
directly on the noradrenergic receptors located on those neurons
(Cedarbaum and Aghajanian, 1977).

Based on this knowledge

clinicians have tried to modify opioid euphoria and withdrawal by
giving drugs which modify these neurotransmitters.
adrenergic antagonist propranolol (Grosz,

The beta

1972), alpha adrenergic

antagonists (Davis and Smith, 1973), and noradrenergic synthesis
inhibitors (Davis and Smith, 1973) all have effects on opioid
withdrawal.

None of these agents has been shown to be as effective

in alleviating the discomfort of withdrawal as the alpha-2 adrenergic
agonist clonidine.
In 1978, Clonidine hydrochloride was used by Gold to successfully
block acute opiate withdrawal symptoms in 11 patients abruptly
withdrawn from methadone maintenance (Gold et al,

1978a).

Patients were given clonidine 36 hours after their last methadone
dose (range = 15-50 mg methadone), when they all had objective
signs of opioid withdrawal.

All patients experienced relief of

abstinence signs and symptoms for 4 to 6 hours after receiving a 5
Mg per kg

dose of clonidine.

In a subsequent study, clonidine

enabled 10 of 10 (100%) patients to successfully withdraw from
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methadone (Gold et al, 1978b).

This technique permitted patients to

detoxify from methadone in less than 2 weeks with fewer symptoms
than they would experience during the usual 4-6 month methadone
detoxification.
It was soon after this clinical success that Aghajanian, using single
neuronal recording techniques and microiontophoresis, reported his
investigation of the mechanism of clonidine as well as of the role of
the LC in opioid withdrawal (Aghajanian, 1978).

He found that

endogenous and exogenous opioids decrease LC firing rates and that
the opioid antagonist naloxone reversed this suppression of the LC.
He observed that chronic opioid administration produced tolerance of
the LC neurons to opioid suppression.
withdrawal produced

the predicted

which was reversible with clonidine.

Naloxone precipitated
noradrenergic

hyperactivity

Furthermore, naloxone

administration overrode morphine's suppression of the LC, but was
unable to override clonidine's suppression of LC firing.

He concluded

that the LC is under the dual contol of opioid and alpha-2 adrenergic
receptors.

Opioid withdrawal produces central noradrenergic

hyperactivity through disinhibition of the LC. This noradrenergic
hyperactivity can be blocked by the alpha-2 adrenergic agonist
clonidine through its action at receptors distinct from the opioid
receptors to which morphine binds.
Subsequent studies have demonstrated that clonidine does not
alleviate withdrawal solely through its inhibition of noradrenergic
firing.

Lesions of noradrenergic neurons do not reduce clonidine's

ability to attenuate behavioral signs of withdrawal (Britton et al,
1984).

The amygdala (Freedman and Aghajanian, 1986), spinal cord
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(Franz et al, 1982), and forebrain (Matsui and Yamamoto, 1984) have
all been proposed as other areas of clonidine’s activity in opiate
withdrawal.
Since the initial studies by Gold (Gold et al, 1978a; Gold et
al; 1978b, Gold et al, 1980), other investigators have demonstrated
clonidine's ability to ameliorate the abstinence syndrome in patients
previously maintained on

methadone with success rates of 80% to

90% (Uhde et al,1980; Kleber et al, 1980; Charney et al, 1981).

In

double blind, placebo controlled studies, clonidine has proven itself
more effective than placebo (Gold et al, 1978b) and as effective as a
20 day methadone taper (Kleber et al, 1985; Washton and Resnick,
1981) in alleviating the signs and symptoms of methadone
withdrawal.

Although it was recommended that shorter acting

narcotics be withdrawn in less than a week using clonidine (Kleber et
al., 1980), no inpatient studies and very few outpatient studies had
examined clonidine's efficacy in detoxification from these agents.
Early attempts at outpatient detoxification using clonidine were
less successful.

In the first double-blind study comparing clonidine

and methadone in an outpatient setting, 31% of patients receiving
clonidine were successfully detoxified from methadone maintenance
compared to the 46% of patients undergoing rapid methadone taper
(Washton and Resnick, 1980).

In a subsequent study by the same

investigators, 31 of 39 (80%) methadone patients and 4 of 11 (36%)
heroin users were successfully detoxified using clonidine, for an
overall success rate of 70% (Washton and Resnick, 1980).

In this

same study, a sub-group of methadone patients was detoxified using
clonidine in conjunction with gradual methadone dose reductions.
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Ten of 20 (50%) patients were successfully withdrawn in this
manner.

Kleber and colleagues also assessed clonidine detoxification

under double-blind conditions (Kleber et al, 1985).

Of 49 methadone

patients whose dose had been lowered to 20 mg, 25 were detoxified
using methadone tapered at 1 mg decrements, and 24 by abrupt
substitution with clonidine.

They found that 9 of 23 (39%) in the

methadone group and 10 of 24 (42%) in the clonidine group achieved
successful detoxification, with one third of the patients successfully
detoxified in both groups maintaining abstinence over the
subsequent six months.

These success rates of outpatient clonidine

detoxification contrasted sharply with the 80% to 90% success rate of
clonidine inpatient detoxification.
Outpatient detoxification using clonidine involves difficulties that
do not arise in an inpatient trial.

First, potential clonidine side

effects such as hypotension and sedation are more difficult to
managed on an outpatient basis.

In an inpatient setting, increased

clonidine doses can be used because of the increased capacity to
monitor side effects.

For this reason, clonidine doses given to

outpatients at Yale have been tapered or held if diastolic blood
pressure dropped below 55, or systolic pressures were lower than
85.

Second, the temptation and opportunity to deal with discomfort

by using narcotics is greater in outpatient settings where these
agents are more readily available.

However, despite these

drawbacks of outpatient detoxification, there are compelling reasons
for improving the efficacy of outpatient therapy: many patients are
unable to be hospitalized for the time required by inpatient
programs; many programs do not have an inpatient detoxification

unit available; finally, inpatient treatment places more stress on
limited medical resources.
In addition to the problem of lower success rates in the outpatient
setting, both clonidine and methadone therapy failed to shorten the
time required for withdrawal.

This was especially problematic in the

outpatient setting, for a long duration of mild withdrawal symptoms
affords outpatients a greater opportunity to resume opioid use.
Previous efforts to shorten the withdrawal period by Blachley and
his colleagues demonstrated that the pure opiate antagonist naloxone
given parenterally to opiate dependent patients precipitated
withdrawal and shortened the period required for this withdrawal
(Blachley et al, 1975).

They noted that the intensity of this

precipitated withdrawal decreased with successive doses of naloxone
with the withdrawal period complete in 1 or 2 days.

Despite their

claims that patients experienced less total discomfort than that
experienced with longer, but more gradual withdrawal, this means of
detoxification was never practiced extensively.

Other groups have

tried this technique (Kurland and McCabe, 1976; Resnick et al, 1977),
but were never able to satisfactorily ameliorate the intensified
withdrawal symptoms with symptomatic medication.
Based on data that clonidine had been noted to block naloxone
induced morphine withdrawal (Meyer and Sparber, 1976),

Riordan

and Kleber combined clonidine and naloxone therapy to successfully
withdraw 3 heroin users and 1 methadone patient over a 4 day
period.

This was accomplished in a three stage procedure.

On day 1,

opioids were withheld and patients received only clonidine; on days
2 and 3, patients received both clonidine and naloxone; on day 4,

12

patients received clonidine and a single evening dose of naloxone to
determine whether they had any persistent opioid tolerance (Riordan
and Kleber, 1980).

All 4 (100%) inpatients were successfully

detoxified using this method.
Naloxone (N-allylnoroxymorphone) is a pure opiate antagonist
effective only when administered parenterally (Eddy and May,
1973).

Although naloxone produces effective blockade of morphine,

this blockade is short lasting and decays completely over a 4 hour
period.

One study has demonstrated naloxone's ability to attain

effective blockade of morphine for nearly 24 hours; however, this
required 3,000 mg per day of naloxone, a
this agent (Zaks et al, 1971).

dangerously large dose of

This short half-life and parenteral route

of administration severely limited the use of naloxone in the
treatment of opioid dependency.
In 1965, Blumberg and Dayton synthesized naltrexone (Ncyclopropyl-methylnoroxymorphone), an analogue of naloxone which
was longer lasting and potent orally (Blumberg and Dayton, 1972).
The principal pharmacologic action of naltrexone is that of an opioid
antagonist.

Naltrexone blocks the action of opioids by competitive

binding at the opioid receptor to displace any opioids present as well
as block the effects of subsequent opioid administration.

To avoid

the precipitation of the opioid abstinence syndrome, it is
recommended that patients using short-acting opioids, such as heroin
and morphine, await 7 days after their last use of that substance
before initiating naltrexone therapy (Kleber et al, 1985a).
Individuals using longer-acting opioids, such as methadone, are
advised to wait 10 days before initiating naltrexone therapy.
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However, the longer the interval before naltrexone is begun, the
greater the chance that the addict will return to opioid use.

Because

of this, investigators have continued to search for treatment
modalities which would both shorten the withdrawal syndrome as
well as enable earlier naltrexone induction.
Charney and his colleagues used clonidine and naltrexone in
combination to provide a safe, effective, and rapid withdrawal for
patients maintained on methadone (Charney, 1982).

Over a 6 day

period, 10 of 11 (91%) patients were able to withdraw completely
from methadone therapy.
in two stages.

This detoxification was also accomplished

On day 1, patients had their regular methadone

maintenance dose held and received clonidine therapy alone.

On

days 2 and 6, patients received oral naltrexone therapy in addition to
clonidine.

The naltrexone was administered in increasingly higher

doses until day 5 when maintenance levels (50 mg) were attained in
a single daily dose.

Clonidine doses had reached a maximum on

days 2 and 3 ( 2.9 +/- 0.6 and 2.3 +/- 0.6, respectively) and were
rapidly tapered on days 4 through 6.
therapy after day 6.

No one required clonidine

Three of the 10 (30%) patients decided to

continue on naltrexone maintenance therapy.

In a follow-up period

ranging from 4 months to one year, only 1 of the 10 patients had
returned to opioid use.

In an extension of this study, Charney

examined a total of 40 methadone patients who were detoxified
using combination clonidine and naltrexone therapy (Charney et al,
1986).

Fourteen (including the 11 from the previous study) were

detoxified using the same two stage dosage regimen described above.
Twenty-six were detoxified in a single stage procedure, eliminating
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the first day of clonidine therapy alone.

Patients in this group

received both clonidine and naltrexone therapy on days 1 through 4
of the study and attained naltrexone maintenance levels (50 mg) by
day 4.

For both groups, naltrexone doses were gradually increased

from 1 mg to 50 mg over a 4 day period.

Thirty-eight of 40 (95%)

patients withdrew from opioids completely over the 4 or 5 day
period.
Combination clonidine and naltrexone therapy has also been
proven effective in the outpatient setting.

Over a 5 day period

Kleber and colleagues successfully withdrew 12 of 14 (86%) heroin
users from opioids while simultaneously initiating naltrexone
therapy (Kleber et al, in press).

This study was conducted using

clonidine and naltrexone doses similar to those used in the previous
inpatient study (Charney et al, 1982; Charney et al, 1986).

An

important difference was a naloxone challenge test (NCT)
administered on the first day of the study.

Unlike the patients in

Charney's study who had been maintained on a known amount of
methadone, patients in this study used illicit opiate preparations
with inconstant opiate concentrations.

The naloxone challenge test

was used to establish opioid dependence in these patients as well as
objectively quantify that dependence (Wang, 1974; Weisen;
Wang 1982).

1977;

This ensured that only opioid dependent individuals

entered the detoxification, and that those who did received adequate
initial clonidine doses.

Of the 12 patients who successfully completed

the 5 day detoxification and the week of naltrexone maintenance, 5
(42%) remained in naltrexone maintenance one month later and 3
others (25%) claimed to be completely drug free.
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These studies demonstrate that combination clonidine and
naltrexone therapy is able to speed the time course of opiate
withdrawal without increasing symptomology (Charney et al, 1982;
Charney et al, 1986; Kleber et al, in press).

In addition, naltrexone

and clonidine detoxification appears to equalize the time course of
the heroin and methadone withdrawal syndromes (Kleber, in press).
Naltrexone is thought to speed the process of withdrawal by rapidly
reversing

opioid-induced

central

noradrenergic

hypersensitivity.

Administration of naltrexone to opioid dependent animals rapidly
reverses morphine-induced increases in the number of brain alpha-2
and beta adrenergic binding sites (Hamburg and Tallman, 1981;
Cedarbaum and Aghajanian, 1977).

Clonidine is able to suppress the

intensified noradrenergic discharge which naltrexone would
otherwise produce, and in this manner alleviate withdrawal
symptomatology.

The clonidine naltrexone protocol appears to

equalize the heroin and methadone withdrawal syndromes by
displacing opioids from binding sites thereby eliminating the effects
of opioid half-life on the time course of central noradrenergic
normalization (Kleber in press).
Outpatient clonidine and naltrexone detoxification is a safe and
effective method of treating opiate withdrawal.

This therapeutic

combination also facilitates follow-up naltrexone maintenance
therapy, effective treatment for the relapsing character of opioid
dependence.

Failure of previous outpatient clonidine detoxifications

to match inpatient success rates may have been due largely to the
greater temptation and opportunity to deal with discomfort by using
opioids which are more available in the outpatient setting.

The
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addition of naltrexone therapy removes this temptation by producing
opioid blockade early in detoxification.

Comparable success rates of

outpatient clonidine and naltrexone detoxification and inpatient
clonidine detoxification support this hypothesis as well as the
conclusion that combination clonidine and naltrexone therapy should
be a more widely practiced treatment for opiate withdrawal.
However, the doses of naltrexone used in the protocol are smaller
than those available commercially.

The purpose of this study was to

develop an outpatient clonidine and naltrexone protocol using
naltrexone doses available to all treatment programs.

Although, the

use of larger naltrexone doses risks precipitation of a more intense
withdrawal and an outpatient setting may limit the amount of
clonidine which may be necessary to ameliorate this withdrawal
syndrome, outpatient detoxification is a desirable mode of treatment
for both patients and physicians.
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MATERIALS AND METHODS
1. SUBJECTS
The patient group included 18 heroin abusers, 10 men and 8
women, treated at the Substance Abuse Treatment Unit of the
Connecticut Mental Health Center, New Haven, Connecticut.

As shown

in table 1, mean age (+/- S.D.) was 30.0 years (+/- 4.1) and mean
duration of opioid use was

8.4

years (+/- 6.3).

Types of opiates

abused included: intravenous heroin (n=16), intranasal heroin (n=3),
intravenous hydromorphone (Dilaudid) (n=2), intravenous
methadone (n=l), oral oxycodone (Percocet) (n=l), and oral
meperidine (Demerol) (n=l).

Of note, 6 of the patients who were

using intravenous heroin stated that they were using synthetic
opiates (i.e.
included:

"Liberty," "Blue Thunder," etc.).

Polydrug abuse

intravenous cocaine (n=7), intranasal cocaine (n=2),

marijuana (n=13), benzodiazepines (n=2),

and alcohol abuse (n=4).

Eleven patients had undergone prior substance abuse treatment
including detoxification (n=8), methadone maintenance (n=3), and
naltrexone maintenance (n=4).

The mean naloxone challenge test

score on the Wang scale (Wang, 1982) was 16.1 (+/-1.5).
All patients participating in the study were in good health as
evidenced by a physical examination, medical history, psychiatric
screening interview, laboratory analysis, and ECG performed one
week prior to the detoxification.

Laboratory analysis included a CBC,

LFT's, VDRL, Hepatitis screening, and urinalysis.

In addition, any

woman participating in the study received a Beta-HCG pregnancy
test.

Candidates were excluded from the study if they: 1) were
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younger than 18 years or older than 45 years, 2) had a systolic blood
pressure greater than 165 or a diastolic blood pressure greater than
110, or were undergoing medical treatment for hypertension, 3)
were receiving current treatment for other medical conditions
requiring ongoing medication, 4) had been treated with tricyclic
antidepressants, MAO inhibitors, or phenothiazines during the two
weeks prior to participation, 5)

were allergic to imidazoline drugs, 6)

had a history of acute or chronic hepatitis, cardiac arrythmias,
rheumatic fever, sinus bradycardia of less than 50 bpm, renal or
metabolic disease, 7) had a history of a severe psychiatric disorder
(e.g., major psychotic episode, schizophrenia, psychotic depression,
bipolar affective disorders), or 8) were pregnant.

(All women

participating in the study had a negative Beta-HCG test within one
week of the study.)

2. TREATMENT SCHEDULE
Patients were divided into two treatment cohorts.

Patients

referred to the Substance Abuse Treatment Unit for detoxification

in

the first half of the study underwent a 5 day detoxification.
Detoxification time was then reduced to 4 days for all patients in the
second half of the study.

On day 1 patients in the first cohort

underwent a naloxone challenge test followed by clonidine therapy
administered three times a day.

On the subsequent 4 days patients

received a combination of clonidine and naltrexone therapy.
Naltrexone was given in a single morning dose on days 2 through 5.
Supplementary clonidine doses were available to patients on days 2
and 3.

For those patients in the second half of the study days 1 and
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2 of the detoxification were combined.

On day 1 patients in the

second cohort also underwent a naloxone challenge test followed by
clonidine therapy administered three times a day.

However, unlike

the original cohort, these patients received their first naltrexone dose
in the afternoon of their first day.
were advanced one day.

All subsequent naltrexone doses

Both protocols are summarized in Table 2.

Patients came to clinic daily at 8-9 am to receive medication,
answer questionaires, and have their blood pressure monitored.
Patients in the first cohort were required to remain in clinic from
8:30 am to 3:00 pm on the first three days of the study so that their
withdrawal symptoms could be followed, blood pressure and heart
rate monitored, and clonidine doses adjusted accordingly.

Patients in

this group were not permitted to work on the second and third days,
and were not permitted to drive on the first three days.
asked to remain at home these first three evenings.

They were

In order to

minimize orthostatic blood pressure effects, patients were instructed
to sit when urinating and to avoid hot showers.

For the second

cohort these restrictions only applied to the first two days.

When a

"significant other" picked the patient up at the conclusion of the first
day of the study, the study was explained to them and they were
asked to sign the patient's consent form.

An investigator was on call

each evening to respond to questions.
While in clinic both groups had their blood pressure monitored
immediately before, 60 minutes after, and 120 minutes after each
clonidine dose.

Subjective and objective abstinence rating scales

were filled out at these times as well as immediately before and 60
minutes after the patient's daily naltrexone dose.

Patients took a
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prescribed evening dose of clonidine home with them as well as 0.1
to 0.3 mg for "prn" doses. They were asked to fill out a subjective
abstinence rating scale at 8:00 pm before taking their evening dose
of clonidine

and also to return extra pills the following morning.

On days 1, 2 and 3 additional clonidine doses were given one hour
following daily naltrexone doses if the patient had 5 or more of the
17 signs and symptoms of withdrawal included in our abstinence
rating scale.

Clonidine doses were tapered or held, if standing

systolic blood pressure was less than 80 mm Hg, if diastolic pressure
was less than 60 mm Hg, or if patients complained of orthostatic
symptoms.
Naltrexone therapy was begun on day 2 for the patients in the
first cohort and was administered at 9:00 am (30 minutes following
the am clonidine dose).

This initial dose was 12.5 mg or one fourth

of the 50 mg scored naltrexone tablet (Trexan).
increased to 25 mg on day
(usually a Friday).
am.

This dose was

3, 50 mg on day 4, and 100 mg on day 5

All naltrexone doses were administered at 9:00

Patients then entered a naltrexone maintenance program the

following Monday to continue their naltrexone therapy.
Patients in the second cohort began their naltrexone on the first
day of the protocol, receiving 12.5 mg of naltrexone at 1:30 pm (30
minutes following their second clonidine dose and two to three hours
following their NCT).

They then received 25 mg at 9:00 am on day 2,

50 mg on day 3, and 50 or 100 mg on day 4 depending on the day of
week and what day they would enter the naltrexone maintenance
program (Tuesday or Thursday patients received 50 mg; Monday,
Wednesday, or Friday patients received 100 mg).
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Patients were given chloral hydrate, 1 gm, as indicated for
insomnia.

For patients who did not respond to chloral hydrate, or

who experienced muscular aching not relieved by clonidine,
flurazepam 30 mg or diazepam 10 mg was prescribed in place of
chloral hydrate.
Urine samples were obtained on days 1, 3, and 5 from the first
cohort and days 1, 3, and 4 from the second cohort.

These were

analyzed to evaluate any use of illicit drugs.

3. NALOXONE CHALLENGE TEST
The degree of a street addict's opiate dependence is difficult to
determine because of unreliable histories and variable opiate
concentrations found in illicit preparations.

Through the naloxone

challenge test we were able to establish opiate dependence as well as
determine the degree of that dependence.

We could then more

reliably estimate initial clonidine doses and ensure a more
comfortable detoxification.

The naloxone challenge test was

described by Wang in 1974 (Wang, 1974) and modified in 1977 and
1982 (Weisen, 1977; Wang 1982).

It consists of an intramuscular

injection of 0.8mg naloxone followed by scoring of withdrawal
symptoms at 10, 20, and 30 minutes.

The Wang rating scale scores

objective symptoms of withdrawal, giving more weight to symptoms
if they appear more rapidly (See Table 3).

Patients received

clonidine after 10 or 20 minutes if their predicted score on Wang's
36 point scale was greater than 9 at those times, otherwise they
received clonidine at 30 minutes.

An additional clonidine dose was

given one hour later if their Wang abstinence score remained above

5.

Patients without symptoms at 10 minutes received an additional

0.8 mg naloxone intramuscularly.

Individuals whose score was less

than 2 at 30 minutes after their second injection of naloxone (total of
1.6 mg naloxone), were told that they did not have a clinically
recognizable acute withdrawal syndrome, were dropped from the
study, and were referred to a naltrexone maintenance program.

Day

1 clonidine doses, based on naloxone challenge test scores, are listed
in Table 4.

4. INSTRUMENTS
Throughout the course of the detoxification, patients' objective
and subjective symptoms of withdrawal were closely monitored
using withdrawal scales from previous detoxification studies at the
Connecticut Mental Health Center (Charney, 1981; Charney, 1982;
Kleber, in press ).

Every morning prior to medications, patients were

asked to complete a withdrawal line, craving line, opiate withdrawal
scale (self-rated), and a self-rated visual analog scale.

The

withdrawal line is a 100 millimeter long horizontal line that
functions as an analogue scale.

The left end of the line is marked "0

- no withdrawal" and the right end is marked "100 - severe
withdrawal."

In addition, patients completed this scale before and

60 minutes following their daily naltrexone dose.

Similar to the

withdrawal line, the craving line is a 100 millimeter horizontal line
with its left end marked "0 - no craving" and the right end marked
"100 - severe craving."

The opiate withdrawal symptom checklist is

a self-rated analogue scale containing 38 statements pertaining to
symptoms of opiate withdrawal (e.g., "My bones and joints have been
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aching") (Haertzen and Meketon, 1968).

Patients rated each of these

statements on a 1 (not at all) to 4 (very much) point scale.
rated visual analogue scale
nervousness,

irritability,

The self-

contains five symptoms (energy,

uninvolvement,

and unpleasantness)

which

patients rated on a l(low) to 7(high) point scale.
In addition to the rating scales completed every morning by the
patients, observer-rated abstinence rating scale (ARS) were
completed for each patient at specific time intervals throughout each
day.

The ARS monitors 17 signs and symptoms associated with opioid

withdrawal (see Table 5).

On the first day of the detoxification, the

ARS was measured before the NCT, immediately after the NCT but
before any clonidine was given, at 30, 60 and 120 minutes after the
initial clonidine dose, and immediately before the 2:00 pm clonidine
dose.

On subsequent days, the ARS was measured in the morning

prior to any medication, before the daily naltrexone dose, 60 minutes
after the naltrexone dose, and immediately before the 2:00 pm
clonidine.
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RESULTS

A. OUTCOME

1. Acute Detoxification
Eighteen patients underwent a naloxone challenge test (NCT).
had

One

a negative challenge test (Wang score below 2 after a total

naloxone dose of 1.6 mg) and was dropped from the study.
seventeen patients

Of the

who entered the protocol, nine began the 5 day

detoxification, and eight began the 4 day detoxification.

Of the nine

patients who entered the 5 day study, eight successfully completed
detoxification (89%) and were discharged on maintenance doses of
naltrexone.

The patient who failed to complete the study had a peak

NCT score of 15.

This score was comparable to the mean peak NCT

score for the patients completing the protocol (15.5 +/-3.3).
Throughout the first day she complained of considerable discomfort
from leg cramps unrelieved by clonidine.

These were relieved in the

afternoon of the first day by warm soaks.

Despite this relief, the

patient failed to return the morning of the second day.

She returned

to the Substance Abuse Treatment Unit and was subsequently
detoxified as an inpatient with methadone.

She then entered the

naltrexone maintenance program for a brief period before leaving to
enroll in methadone maintenance.
Of the eight patients who entered the 4 day study, six successfully
completed detoxification (75%) and were discharged on maintenance
doses of naltrexone.

The two patients who failed to complete the

study were similar in that they both experienced less discomfort
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than most patients, but failed to return for the fourth and final day
of the protocol.

The first had a NCT score of 16 at 10 minutes,

comparable to the mean peak NCT score (+/- S.D.) of 17.0 (+/- 3.3) for
the patients completing the protocol.

This patient returned to clinic

on the following day (day 5) stating that he had used intravenous
heroin the preceding evening (confirmed by urine toxicology screen).
Repeated efforts to restart him on naltrexone were unsuccessful.
second patient

The

had a peak NCT score of 9 after 1.6 mg of naloxone.

She never returned to the clinic despite repeated efforts by phone to
reestablish contact.

Of note, because these patients had completed 3

days of the 4 day protocol, they had achieved a maintenance dose of
naltrexone (50 mg/day).

2. Follow-up
Six of the eight patients (75%) completing the 5 day protocol
began naltrexone maintenance the week following their
detoxification.

Both of the patients who had failed to enter

naltrexone maintenance had moved out of the area that same week.
Arrangements had been made for one of these patients to enter
naltrexone maintenance in the area to which she was moving;
however, she failed to report to that naltrexone maintenance
program.
patients

One month after completing the protocol, five of these six
remained in naltrexone maintenance.

Four of the six patients (67%) completing the 4 day protocol began
naltrexone maintenance the week following their detoxification.

One

month after completing the protocol all four of these patients
remained in naltrexone maintenance.

The two patients who failed to

26
enter a naltrexone maintenance program were again using opioids
one month after completing the detoxification.

B. RESPONSE TO OPIOID ANTAGONISTS (NALOXONE AND
NALTREXONE)
Opioid antagonists precipitated significant withdrawal symptoms,
but symptoms were adequately relieved by clonidine.

The mean

Wang score for all patients following the NCT was 16.1 (+/- 5.1),
corresponding to a methadone dose requirement of 40 mg/day by
Wang's criteria (Wang 1982).

On day 1, both cohorts responded well

to clonidine given at 10 or 20 minutes (depending on the patient's
NCT score) following the intramuscular naloxone.

By 30 minutes

after receiving clonidine patients in both cohorts had experienced
symptom relief as demonstrated by the abstinence rating scale
(ARS).

Two hours after the first oral dose of clonidine, patients in

both cohorts had lower ARS scores than prior to the NCT.

This

reflects both the efficacy of clonidine in relieving symptoms as well
as the half-life of naloxone (approximately 60 minutes).
Patients in cohort 2 received their first dose of naltrexone
(12.5mg) on the first day, two hours after receiving their initial dose
of clonidine.

Of note, only two patients (NCT scores= 20 and 6)

experienced an increase in their ARS scores 60 minutes after this
naltrexone dose.

Even with the increase, each of these patients' ARS

scores were less than 5.
Patients in the first cohort received their first dose of naltrexone
(12.5mg) on the second day, 30 minutes following their morning dose
of clonidine.

Only one patient (NCT score=16) experienced an
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increase in symptoms, and these symptoms responded well to a
supplementary clonidine dose.
Both groups of patients experienced a rise in their ARS score the
morning of their second day before any medication had been given.
This responded well to the morning dose of clonidine, and probably
represented the time lag between their 8pm and 9am dose of
clonidine.

Although many had taken 0.1-0.2mg of clonidine for

discomfort during the night, this was still less than their regular
clonidine dose.

This morning pre-medication rise in ARS score was

also experienced on day 3 by the patients in the 5 day detoxification.
This was not experienced on days 3 or 4 by those in the 4 day
detoxification, when they were receiving a maintenance dose of
naltrexone (50mg and 50 to lOOmg, respectively).
Unlike patients in the 4 day detoxification, those in the 5 day
detoxification experienced transient rises in ARS on days 3 and 4,
sixty

minutes following their daily naltrexone dose.

When patients'

ARS exceeded a score of 5, they were given supplementary doses of
clonidine and responded well to them.

On day 5, all patients

received 100 tol50 mg naltrexone without any symptoms.

C. ABSTINENCE SYMPTOM RELIEF
The treatment regimen effectively suppressed signs and
symptoms of withdrawal.

On no day was the mean number of signs

and symptoms greater than 5 out of the 17 included in the
abstinence rating scale (Figure 1).

Persistent symptoms were

anxiety, restlessness, insomnia, muscle aches, and "yen" for sleep.
Often the signs and symptoms reported were mild in nature.
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Through the course of the detoxification patients experienced
significant symptom relief (5 day detoxification F(5,47)=6.6, pc.005; 4
day detoxification F(4,29)=4.5, pc.01).

There was no significant

difference between the two groups (treatment F(l,63)=.3).

There

was a significant correlation between NCT score and mean ARS scores
for patients in both groups on days 1 and 2 (Day 1, p c .05; Day 2, p c
.01), which accounted for 30% to 45% of the variance in ARS.
Patient ratings of withdrawal (Figure 2), indicated that the
withdrawal process was relatively comfortable for the majority of
patients.

On this scale, the mean withdrawal line for those in the 4

day detoxification was significantly higher than for those in the 5
day (treatment F=6.3, pc.025). This difference was also shown on the
opiate withdrawal scale (treatment F= 16.5, pc.005), another patient
rated analogue scale shown in Figure 3.

However, elimination of

baseline differences by examination of the percentage change from
day 1 of these withdrawal scale scores demonstrates no difference
between the two treatments (Figure 3B).

Craving lines (Figure 4) and

patient rated analogue scales (Table 6) for both detoxification groups
did not differ or change significantly over the course of the
detoxifications.

D. BLOOD PRESSURE CHANGES AND SIDE EFFECTS OF CLONIDINE
The effects of the clonidine-naltrexone treatment on standing
systolic and diasolic blood pressure and standing and supine heart
rate are summarized in figures 5 through 8.

As shown in Figure 5,

clonidine significantly lowered systolic blood pressure for both
groups (4 day detoxification F(5,35)= 6.0, pc .005; 5 day
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detoxification F(6,55)=2.6, p<.05).

On days 1 through 4 for those in

the 5 day detoxification, and days 1 through 3 for those in the 4 day
detoxification, systolic blood pressure differed significantly from the
"initial" values (paired t test pc.01).

The decrease in systolic blood

pressure for those in the 4 day detoxification was not significantly
greater than that for those in the 5 day detoxification (F=2.6, pc.25).
Clonidine significantly lowered the diastolic blood pressure (Figure 6)
of the patients in the 4 day protocol (F(5,35)=5.4, pc.005); however,
the diastolic blood pressure of patients in the 5 day protocol was not
significantly lowered (F(6,55)= 2.1, pc.l).

Diastolic blood pressure on

days 1 through 4 for patients in both detoxification groups differed
significantly from "initial" values (paired t test pc.005 to pc.025).

As

shown in figures 7 and 8, clonidine did not significantly alter
standing and supine heart rates of patients in the 4 day
detoxification (standing F(5,35)=.6; supine F(5,35)=1.9).

The standing

heart rate (figure 7) of patients in the 5 day detoxification was not
significantly decreased by clonidine (F(6,55)=.8); however, supine
heart rate (Figure 8) was significantly decreased by clonidine
(F(6,55)=2.7, pc.05).

This is probably reflective of the bradycardic

effects that clonidine may produce at rest which are overridden
when standing or exercising (Pettinger, 1975).

There were no

syncopal episodes during the course of treatment; however, most
patients reported dizziness on standing during days 2 and 3.

There

was no significant difference between the groups in mean total
clonidine required per day.

In both groups, patients with NCT scores

greater than 20 did not have significantly larger decreases in blood
pressure or heart rate than did patients with NCT less than 20.
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Other commonly reported side effects from clonidine were dry
mouth and sedation.

E. PATIENT COMPLIANCE
Patients took evening clonidine doses as instructed and returned
unused clonidine in the morning when they reported to clinic.

One

patient in the 5 day detoxification used intravenous heroin on the
evening of the first day.

She was allowed to continue in the protocol

and experienced no adverse effects when she received the full
scheduled dose of naltrexone on the second day.

Two patients in the

4 day detoxification used intravenous cocaine on the afternoon of the
third day (confirmed by urine toxicology screen) and experienced
euphoria.
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DISCUSSION

1. CLINICAL OUTCOME
The clonidine-naltrexone outpatient detoxification enabled 14 of
17 (82%) opioid dependent patients to completely withdraw from
short acting opioids within a 4 or 5 day period and simultaneously
begin naltrexone maintenance.

This success rate is higher than that

achieved using either of the standard methods of outpatient
detoxification: gradual methadone taper (13% to 46 %) (Wilson, 1974;
Wilson, 1975; Silsby, 1974; Senay and Dorus, 1981; Washton and
Resnick, 1981), or clonidine alone (31% to 40%) (Washton and
Resnick, 1981; Kleber, 1985).

The results of this study are

comparable to the success rate achieved in a similar outpatient
regimen enabling 12 of 14 (86%) heroin users to withdraw from
opioids in 5 days (Kleber, in press).

Although the earlier study also

enabled a high percentage of patients to withdraw from short acting
opioids and attain maintenance levels of naltrexone on an outpatient
basis, the present 5 or 4 day detoxification allowed a more rapid
withdrawal with a simplified,
regimen.

single-dose-per-day naltrexone

Such a regimen significantly reduced the period of time

patients spent in clinic without significantly increasing daily
clonidine doses or changes in blood pressure.
Comparison of the two detoxification groups in this study
demonstrate that initiating naltrexone therapy sooner significantly
shortened the withdrawal
rated symptomatology.

syndrome without increasing observer-

Patients in the 5 day detoxification began

naltrexone therapy on the second day of the detoxification with
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maintenance levels (50 mg) achieved by the fourth day.

Patients in

the 4 day group began naltrexone therapy on the first day of the
detoxification and achieved maintenance levels by the third day,
forty-eight hours after their last opioid use.

Comparison of the

abstinence rating curves of both groups (Figure 1) shows almost
complete abstinence relief in the third day of the protocol for those
in the 4 day study, a level achieved on the fourth day by those in the
5 day study.

Another advantage of receiving naltrexone on the first

rather than second day of detoxification was that patients were less
likely to use opioids in the early stages of the detoxification, before
complete opioid blockade had been achieved.
Although there was no significant difference between the two
groups in observer-rated withdrawal symptomatology, there was a
significant difference in patient-rated symptomatology (Figures 2
and 3).

Because there were significant baseline differences between

the two groups on both these withdrawal scales, the baseline
differences were adjusted by examining percentage change from day
1 (Figures 2B and 3B).

With this adjustment, no significant

difference was found between the treatments.
The clonidine and naltrexone combination worked well in the
outpatient setting.

Signs of opioid withdrawal were rarely seen, and

patients reported mild withdrawal symptoms.

The symptoms not

relieved by clonidine were primarily restlessness, muscle aches, and
insomnia, which were more likely to persist in patients with higher
NCT scores.

Those in the 4 day study with persistent restlessness or

muscle aches were prescribed diazepam 10 mg twice a day on days 1
and 2.

They experienced significant relief from this intervention.
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Clonidine significantly lowered standing blood pressures on the first
three days of the study for each group; however, no clinical problems
resulted from this and patients were not working or driving on these
days.

Many patients in both groups requested that clonidine doses

be held by the fourth day of the protocol to alleviate the sedation
that they were experiencing.

At this time in the study, clonidine

doses could be quickly tapered without the consequence of
withdrawal symptoms arising or rebound hypertension occurring
(Pettinger, 1975; Pettinger, 1980; Hansson, 1973).
Limitations of outpatient treatment emerged.

Of the three

patients who withdrew from the study, two had already attained
maintenance levels of naltrexone.

One of these two patients was

relatively asymptomatic, but failed to return to clinic the morning of
the fourth and final day.

The following week he returned to the

outpatient clinic, but never began naltrexone maintenance.

His

failure to complete the detoxification despite achieving maintenance
naltrexone levels with mild withdrawal symptomatology probably
reflects the ambivalence many addicts have about remaining drugfree; it is unclear whether inpatient detoxification would have been
more successful in detoxifying this patient.

The other patient had

the lowest NCT score, with a maximum of 8, 10 minutes after
receiving her second 0.8 mg dose of naloxone (total naloxone dose =
1.6 mg).

She had been dependent on oral oxycodone and

experienced considerable gastrointestinal cramps on the second and
third days of the protocol, which were unrelieved by clonidine.

The

anticholinergic, antispasmodic agent atropine 0.4 mg was prescribed
three times a day in an effort to counteract the rebound increase in
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gastrointestinal activity probably responsible for her discomfort
(Lord, 1977; Burks, 1976); however, this was also ineffective.
Although somewhat milder, the abstinence syndrome associated with
oxycodone resembles that of morphine and lasts approximately 7
days (Charney and Kleber, 1980).

Gastrointestinal cramping may

have been more of a problem for this patient because the oral route
of her opioid administration would sensitize her gastrointestinal
opioid receptors to a greater degree than intravenous or intranasal
routes.

This would be a phenomenon unique to oxycodone, since

detoxification from oral methadone does not produce such
gastrointestinal discomfort even when withdrawal is precipitated
using the clonidine naltrexone combination (Charney, 1982).

In a

previous study using clonidine to detoxify a patient addicted to
oxycodone, the patient did not complain of any gastrointestinal
discomfort throughout the detoxification (Charney and Kleber, 1980).
It is possible that the addition of naltrexone, an oral opioid
antagonist, so early in the detoxification of these patients may
precipitate significant gastrointestinal symptoms through its
antagonistic action directly on their sensitized gastrointestinal opioid
receptors.

Clonidine therapy alone may be the detoxification of

choice in oral oxycodone users followed by institution of naltrexone
maintenance when their gastrointestinal opioid receptors are not as
sensitive to its effects.
The third patient who did not complete the detoxification began
the 5 day study but did not return after the first day.

She had a NCT

of 16, and experienced considerable muscle cramps in her legs
throughout the first day,

which were eventually relieved by warm
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soaks.

In later detoxifications, diazepam, 10 mg twice a day, was

successful in alleviating persistent muscle cramps which some
patients experienced.

This lack of intervention may have affected

her continued participation in the study.
Unlike the previous clonidine-naltrexone outpatient
detoxification, this protocol did not include a week of naltrexone
therapy following the detoxification.

Instead, patients continued

naltrexone maintenance at one of the two naltrexone maintenance
programs offered by the Substance Abuse Treatment Unit.

Ten of 14

(72%) patients who completed the detoxification returned for
naltrexone maintenance.

In the week following detoxification,

patients had their blood pressures measured and signs and
symptoms rated using the abstinence rating scale.

Only two patients

complained of symptoms sometimes associated with the stabilization
period of naltrexone therapy (Hollister, 1981; Kleber and Kosten,
1984).

2. NALOXONE CHALLENGE TEST {NCT}
The naloxone challenge test (NCT) established opioid dependence
in patients requesting detoxification.

One of the 18 (5.6%) patients

who entered the study had a negative NCT, a rate less than the 15%
to 34 % of negative naloxone challenges found in patients applying
for methadone maintenance (Blachley, 1973, Wang, 1982).

The NCT

also served to guide initial clonidine doses by quantifying the degree
of patients’ dependence.
directly with NCT scores.

Day 1, 2, and 3 clonidine doses varied
Although NCT scores aided in the

determination of clonidine doses,

abstinence rating scale (ARS)
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scores as well as blood pressure measurements ultimately
determined how much clonidine patients would receive.

This

flexibility in clonidine doses ensured a safer and more effective
detoxification.
This study demonstrated a significant correlation between NCT
and ARS scores for patients on the days 1 and 2 of the study (Day 1,
p < .05; Day 2, p < .01).

The NCT, a measurement of the degree of a

patient's addiction, accounted for 30% to 45% of the variance in ARS
scores on those days.

3. MECHANISM OF ACTION OF CLONIDINE AND NALTREXONE IN
OPIOID WITHDRAWAL
Clonidine attenuates the opioid withdrawal syndrome by
suppressing the rebound noradrenergic hyperactivity which occurs
when chronic opioid administration ceases (Korf, 1974; Llorens, 1978;
Maas, 1979).

It accomplishes this by binding presynaptically to

alpha-2 adrenergic receptors, mimicking feedback inhibition to the
locus coeruleus, the brain's major noradrenergic nucleus (Aghajanian,
1978; Crawley, 1979; Nathanson and Redmond, 1981; Laverty and
Roth, 1981).

Since lesions of noradrenergic neurons do not reduce

clonidine's ability to decrease some behavioral signs of opioid
withdrawal, mechanisms other than this presynaptic one have also
been postulated (Britton, 1984).

Recent studies suggest that

clonidine also has anti-withdrawal effects on the amygdala
(Freedman and Aghajanian, in press), spinal cord (Franz, 1982), and
the forebrain (Matsui and Yamamoto, 1984).

37

Naltrexone precipitates withdrawal by binding to opioid
receptors.

This produces a rapid reversal in the morphine induced

increase in the number of alpha-2 and beta receptors (Hamburg and
Tallman, 1981) as well as reversing the opioid agonist induced
deficiency in endogenous opioid function (Kosterlitz and Hughes,
1975). These changes should produce a briefer, less severe
withdrawal syndrome.
Naltrexone also appears to equalize the time course of heroin and
methadone withdrawal (Charney, 1982; Charney, 1986; Kleber, in
press).

The effects of naltrexone on methadone pharmacokinetics

may be related to the reduction in the duration and symptoms of
methadone withdrawal.

Naloxone is thought to increase serum

methadone levels in addicted patients by displacing methadone from
opioid receptor sites (Resnick, 1979).

Investigators have postulated

that the clonidine-naltrexone regimen equalizes the length of the
heroin and methadone withdrawal syndromes by this same
mechanism.

By displacing opioids from binding sites, naltrexone

would eliminate the effect of opioid half-life on the time course of
central noradrenergic normalization and of the withdrawal syndrome
(Kleber, in press).
In previous studies, administration of clonidine and naltrexone in
combination to opioid dependent patients dramatically shortened the
withdrawal

syndrome without significantly increasing patient

discomfort (Charney, 1982; Charney, 1986; Kleber, in press).
present study demonstrates that naltrexone,

The

administered even

earlier in detoxification, continued to shorten the withdrawal
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syndrome

without dramatically

altering

withdrawal

symptomatology.
An interesting effect of the addition of larger doses of naltrexone
to the detoxification has been the decrease in the amount of clonidine
required.

Table 7 demonstrates the difference in mean daily

clonidine doses for both inpatient and outpatient detoxifications
using clonidine.

Kleber and colleagues used clonidine and naltrexone

in combination to detoxify heroin addicts.

Naltrexone therapy began

on day 2 using 1 mg doses which were increased every 4 hours by 1
mg increments.

This detoxification used significantly more clonidine

than both the 4 and 5 day studies ( 4 day, p < .001; 5 day, p < .01).
This difference might be explained by the difference in naltrexone
dosage regimens.

Patients in Kleber's study were given multiple

small doses of naltrexone on days 2 and 3.

This study administered

the same total daily amount of naltrexone in a single morning dose.
Small numerous doses like those used in Kleber's study might
precipitate withdrawal repeatedly throughout days 2 and 3,
increasing patient's
more total clonidine.

withdrawal

symptomatology and necessitating

A single large dose of naltrexone, although it

initially precipitates withdrawal, is enough to remain on more opioid
receptors for a longer period of time.
repeatedly

throughout the day,

Withdrawal is not precipitated

patients withdrawal

symptomatology

is not increased, and patients do not require additional clonidine.
Lower clonidine doses, especially in the outpatient setting, is an
additional advantage of this present study.
Charney's studies detoxified patients from methadone
maintenance (Charney, 1981; Charney, 1982).

Both the patients
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given clonidine therapy alone (Charney, 1981) and the patients given
combination clonidine and naltrexone (with the naltrexone given in
multiple, small doses), required significantly more clonidine than the
4 and 5 day regimens described here (p < .001).

This probably

reflects the difference in the amount of clonidine required to
detoxify patients from long-acting opioids such as methadone

versus

the clonidine required to detoxify patients from short-acting opioids
such as heroin.

When identical naltrexone dosage regimens are used

and the amount of clonidine required per day to detoxify patients
from methadone (Charney, 1982) is compared to the amount of
clonidine per day required to detoxify heroin addicts (Kleber, in
press), a significantly greater amount of clonidine is required to
detoxify methadone patients( p<.001).

4. CLINICAL IMPLICATIONS
Although not definitive treatment for opioid dependence,
withdrawal is the first step towards opioid abstinence.

Methadone

taper, clonidine therapy alone, and clonidine and naltrexone in
combination are all effective therapeutic strategies developed
towards this goal.

Although equivalent to outpatient methadone

taper, the efficacy of clonidine alone has been less favorable in
outpatient than inpatient studies (Kleber et al., 1985).

Combination

clonidine and naltrexone therapy has been shown effective in both
the inpatient and outpatient settings (Charney, 1982, Kleber et al., in
press).

However, these previous studies used small, multiple dose

per day naltrexone regimens which could be conducted only by
programs which had access to liquid naltrexone, a form not
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commercially available.

This study has further improved the

availability of the clonidine-naltrexone combination by using a single
dose per day naltrexone regimen with naltrexone doses available to
any opioid treatment facility.

Day 1 naltrexone doses are 12.5 mg,

one quarter of the scored 50 mg naltrexone tablet (Trexan).

As the

study was conducted, some additional advantages became evident:
the withdrawal syndrome produced by this detoxification was
significantly shortened without significantly increasing patient
discomfort at any point; no more clonidine was required by the
patients in the 4 day study than what was needed by those in the 5
day study or previous clonidine-naltrexone studies (Charney et al.,
1982; Kleber, in press); patients spent less time in clinic but
continued to receive adequate monitoring of hypotension and
sedation, both potentially dangerous side effects of clonidine; the
clonidine naltrexone outpatient detoxification was effectively
integrated with an outpatient naltrexone maintenance clinic so that
maintenance doses of naltrexone as well as outpatient counseling
could be continued without interruption.
This study demonstrated that combination clonidine-naltrexone
therapy using commercially available doses of naltrexone is an
effective therapeutic avenue in outpatient heroin detoxification.

The

time course and patient comfort of this regimen make it a useful,
attractive, and efficacious outpatient method for treating the acute
opioid withdrawal syndrome.

This technique can now be more

widely used in the treatment of opioid dependence.

In

detoxifications which are not conducted for research purposes, a NCT
would not be needed to substantiate opioid dependence.

Neither

41

clonidine nor naltrexone possess any agonistic activity at opioid
receptors and no addictive potential, qualities of methadone that
previously attracted "pseudoaddicts" to enlist in methadone
maintenance.

Instead, 0.2 mg clonidine three times a day could be

administered on day 1, and modifications could be made based on a
patient's blood pressure and abstinence rating scale measurements.
Examination of this revised clonidine dosage schedule as well as
treatment of methadone maintained patients with an outpatient
protocol are the next logical steps in the investigation of this
treatment regimen.
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TABLE 1
Characteristics

of

Patients

Characteristic

5 Dav Detox

4 Dav Detox

Age

29.9 (+/-3.8)

30.1 (+/-4.5)

Male
Female

5
4

5
4

Years of Opioid
Use

8.8 (+/-1.2)

8.0(+/-1.5)

Polysubstance
Abuse

5

9

Previous Treatment
Methadone
Naltrexone

5
2
2

5
1
3

15.5(+/- 3.3)*

15.9(+/-2.3)* #

Sex

NCT Score

*Mean NCT of all those beginning study. Mean NCT of those who
completed 5 day detoxification was unchanged; however, mean NCT
for those who completed 4 day detoxification was 17.0 (+/-3.3).
#N = 8, one patient in this group had a negative NCT
Note: NCT = naloxone challenge test score from Wang (1982) with
range = 0-36 (see Table 3).
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TABLE 3
Rating

Scale

of Withdrawal Symptoms
Naloxone*

after

.8mg

IM

Score for presence or absence of symptomotologv:
10 min.
Symptomatology_Present
Gooseflesh
Vomiting
Tremor
Profuse sweating
Restlessness
Lacrimation and
nasal congestion
Uncontrollable
yawning

Absent

20 min.

30 min.

Present Absent

Present Absent

0
0

2
2
2
2
2

0
0
0
0
0

1
1
1
1
1

3

0

2

0

1

0

3

0

2

0

1

0

3
3
3
3
3

0
0
0

*from Wang (1982); maximum score = 36

0
0
0
0
0
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TABLE 4

DAY 1 CLONIDINE DOSES

Predicted NCT Score
(10

minutes)

Oral Clonidine HCL (mg)
8-10 am

2 pm

8 pm

>18

0.3

0.1-0.2

0.2

9-17

0.2

0.1

0.1-0.2

<9 but >0

0.1-0.2

0.1

0.1
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TABLE 5
ABSTINENCE RATING SCALE

Subjective

Symptoms

Craving
Anxiety
Restlessness
Insomnia
Muscle Aching
Anorexia
Nausea
Hot and Cold Flashes

Objective Symptoms
Rhinorrhea
Tremors
Perspiration
Yawning
Yen for Sleep
Gooseflesh
Vomiting
Diarrhea
Lacrimation
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TABLE 6
PATIENT- RATED ANALOGUE SCALES
SCALES
ENERGY NERVOUS IRRITABILE UNINVOLVED UNPLEASANT
5D 4D

5D 4D

5D 4D

5D 4D

5D 4D

1

2.9 2.2

2.8 3.2

2.5 3.2

2.9 1.8

2.3 2.5

2

1.6 2.5

2.5 4.0

3.4 3.0

3.8 3.5

3.4 3.0

3

2.3 3.7

2.3 3.5

2.8 3.0

2.9 2.7

3.8 2.3

4

4.0 3.7

2.0 2.5

2.0 3.2

1.8 2.5

1.6

5

3.9

2.1

2.1

2.1

2.4

COHORT
DAY

_

_

Note: 5D = 5 day detoxification
4D = 4 day detoxification

_

-

1.6
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TABLE 7
COMPARISON OF DAILY CLONIDINE DOSES (MEAN +/-SD)

A
4 Day

B
5 Day

C
Kleber,
in press

1

0.5 +/-0.2

0.5 +/-0.1

0.5 +/-0.2

1.1

+/-0.2

1.0 +/-0.2

2

0.5 +/-0.2

0.6 +/-0.1

1.1 +/-0.5

2.9 +/-0.6

1.0 +/-0.2

3

0.3 +/-0.1

0.4 +/-0.1

0.6 +/-0.3

2.3 +/-0.6

1.0 +/-0.2

4

0.3 +/-0.8

0.1

+/-0.1

0.3 +/-0.3

0.9 +/-0.2

1.1 +/-0.3

5

_

0.3 +/-0.5

0.2 +/-0.2

0.5 +/-0.3

1.1 +/-0.3

+/-0.1

0.2 +/-0.1

1.1 +/-0.3

Study

D
Charney,
1982

E
Charney,
1981

Day

6

0.1

Note:
4 Day = 4 days of combination clonidine and naltrexone therapy
with naltrexone given in a single morning dose.
5 Day = 1 day of clonidine therapy (after NCT) followed by 4 days of
combination clonidine and naltrexone therapy with naltrexone given
in a single morning dose.
Kleber, in press = 1 day of clonidine therapy (after NCT) followed
by 4 days of combination clonidine and naltrexone therapy with
naltrexone given in multiple small doses throughout the day.
Charney, 1982 = same as Kleber, in press, but inpatient study
detoxing methadone patients.
Charney, 1981 = inpatient study using clonidine alone to detoxify
methadone patients.
Analysis by Z test showed significant differences between A and B
(days 2 - 4, p < .01), A and C (days 2 - 4, p < .001), A and D (days 1 4, p < .001), A and E (days 1 - 4, p < .001), B and C (days 2 and 5, p <
.001; days 3 and 4, p < .01), B and D (days 1 - 5, p < .001), and B and E
(days 1 - 5, p < .001).
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FIGURE 1

Abstinence Rating Scale, mean

ABSTINENCE RATING SCALE (MEAN) VS DAY

Day

50

Figure 1 : Abstinence Rating Scale (Mean) per Day
Mean number of signs and symptoms per patient per day, as rated
on the 17 item observer-rated abstinence rating scale.
The two
detoxification groups were analyzed by 2-way ANOVA for repeated
measure for the first 4 days. Time effect: F(3,63)=15.1, pc.0001;
Treatment effect: F(l,63)= .3, p>.25; Interaction: F(3,63)=1.9, pc.25).
1-way ANOVA analysis of each detoxification showed significant
changes in mean ARS per day over the 4 or 5 days (5 day F(5,47)=6.6
pc.005; 4 day F(4,29)= 4.5, pc.01).
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FIGURE 2

Withdrawal Line (mean), mm

WITHDRAWAL LINE (MEAN) VS DAY

Day
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Figure 2: Mean Withdrawal Line per Day
Mean withdrawal line measurement for each day.
The "withdrawal
line" is a horizontal 100 millimeter line that functions as an analogue
scale. The left end is labeled "0- no withdrawal" and the right end is
labeled "100- severe withdrawal."
Curves represent mean scores for
patients in the 5 or 4 day detoxification. The two plots are
significantly different as analyzed by 2-way ANOVA for repeated
measures for the first 4 days. Treatment: F(l,63)=6.3, pc.025; Time
effect: F(3,63)=8.5, pc.005; Interaction: F(3,63)=3.3), pc.05).
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FIGURE 2B

Withdrawal line (mean)

PERCENTAGE INCREASE WITHDRAWAL LINE (MEAN)

Day

Figure 2B: Percentage Increase Opiate Withdrawal Line
(mean) ner Dav
Percentage increase from day 1 opiate
withdrawal line for each day. The two detoxifications are not
significantly different by 2-way ANOVA for repeated measure for
the first 4 days (treatment: F(l,63) = .629, p > .25). There was a
significant time effect and interaction (time effect: F(3,63) = 6.4, p
.005; interaction: F(3,63) = 3.3, p < .05).
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FIGURE 3
WITHDRAWAL SCALE (MEAN) VS DAY
-t

Withdrawal scale (mean)
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Figure 3: Mean Opiate Withdrawal Scale per Day
Mean opiate withdrawal scale score for each day. The opiate
withdrawal scale is a symptom checklist that functions as a selfrated analogue scale.
It contains 38 statements pertaining to opiate
withdrawal (e.g., "My bones and joints have been aching") which
patients rate on a 1 (not at all) to 4 (very much so) point scale. The
highest possible score is 152 points. The two detoxifications are
significantly different by 2-way ANOVA for repeated measure for
the first 4 days(treatment: F(l,63)=16.5, pc.005; time effect:
F(3,63)=3.6, pc.025); however, there was not a significant interaction
(F(3,63), p>.25). Only the 5 day detoxification showed a significant
change per day as analyzed by 1-way ANOVA for repeated measures
(treatment: F4,39)=4.5, pc.01).
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FIGURE 3B

Percentage change (mean)

PERCENTAGE INCREASE WITHDRAWAL SCALE (MEAN)

Day
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Figure 3B: Percentage Change Opiate Withdrawal Scale (mean) per
Day Percentage change from day 1 opiate withdrawal scale for each
day. The two detoxifications are not significantly different by 2-way
ANOVA for repeated measure for the first 4 days(treatment: F(l,63)
= .105, p > .25). There was a significant time effect and interaction
(time effect: F(3,63) = 5.9, p < .005; interaction: F(3,63) = 4.5, p < .01).

Craving line (mean), mm

59

FIGURE 4

Day

I
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Figure 4 : Mean Craving Line per Dav
Mean craving line measured each morning (prior to the
administration of any medications) for each day. The craving line is
a 100 millimeter horizontal line with its left end labeled "0 - no
craving" and its right end labeled "100 - severe craving." Ratings
significantly decreased over time for both groups by 2-way ANOVA
for repeated measures for the first 4 days(F(3,63)=4.8, p<.01). The
two detoxifications did not differ significantly.
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FIGURES

Systolic Blood Pressure(mean), mmHG

SYSTOLIC BLOOD PRESSURE (MEAN) PER DAY

Day
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Figure 5: Mean Systolic Blood Pressure (Standing) per Day
Standing systolic blood pressure(BP) for each day. Day "0" represents
"initial" systolic BP, which is the mean for all subjects of two
measures; one taken the morning of the first day of the detoxification
prior to the administration of any medications, and the other taken
at least three days prior to each patients entry into the study. The
measurements corresponding to ".5 day" represent each patients
systolic BP immediately after the NCT prior to the administration of
any clonidine.
Day 1 measurements represent the mean of all
systolic BP measurements taken at least one hour after the NCT and
initial clonidine dose. Overall changes in systolic BP were significant
as analyzed by 1-way ANOVA for repeated measures (5 day
treatment F(5,35)=2.6, p<.05; 4 day treatment F(5,35)=6.0, pc.005).
By 2-way ANOVA for repeated measures there was not a significant
difference between treatments for the first 4 days (treatment:
F(l,95)=2.6, pc.25; interaction: F(5,95)= .7, pc.25).
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FIGURE 6

Diastolic BP (mean), mmHg

DIASTOLIC BLOOD PRESSURE(MEAN) PER DAY

Day
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Figure 6: Mean Diastolic Blood Pressure (Standing)
Standing diastolic blood pressure (BP) for each day. Graph
clarifications as in figure 5. The two groups were significantly
different (treatment: F(l,95)=5.8, pc.025) and had a significant
change over time (F(5,95)= 8.2, pc.0001) as analyzed by 2-way
ANOVA for repeated measures for the first 4 days; however, there
was not a significant interaction (F(5,95)=.3, p>.25).
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FIGURE 7

Standing HR (mean), beats/min.

STANDING HEART RATE (MEAN) PER DAY

Day
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Figure 7 : Mean Heart Rate (Standing) per Dav
Mean standing heart rate (HR) for each day. Graph clarifications as
in figure 5. For each detoxification group, overall changes in standing
HR were not significant as analyzed by 1-way ANOVA for repeated
measures. Also, the two groups were not significantly different as an
alyzed by 2-way ANOVA for repeated measures for the first 4 days.
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FIGURE 8

Supine HR (mean), beats/min.

SUPINE HEART RATE (MEAN) PER DAY

Day
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Figure 8: Mean Heart Rate (Supine) per Day
Mean supine heart rate (HR) for each day. Graph clarifications as in
figure 5. For patients in the 5 day detoxification, overall changes in
supine HR were significant as analyzed by 1-way ANOVA for
repeated measures (F(6,55)=2.7, pc.05). There were no significant
changes in supine heart rate for patients in the 4 day detoxification
by this analysis. The two groups differed significantly (F(l,95)=3.9,
pc.05) and had a significant change over time (F(5,95)=6.0, pc.005) as
analyzed by 2-way ANOVA for repeated measures. There was not a
significant interaction (F(5,95)=.6, p>.25).
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